Gyre Therapeutics, Inc. (GYRE) Stock Score, Valuation & Financial Research
Gyre Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 31/100.
Quick answer for GYRE
Gyre Therapeutics, Inc. currently has a Wall Street Score of 31/100. The stored market price is $6.73. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Gyre Therapeutics, Inc. does
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, wh
GYRE financial snapshot
- Wall Street Score:
- 31/100
- Current price:
- $6.73
- Market capitalization:
- $750.3M
- Revenue:
- $119.4M
- Net income:
- $-17.3M
- Free cash flow:
- $-180K
- Cash:
- $43.3M
- Total debt:
- $3.4M
- EPS:
- 0.06
- P/E ratio:
- 119.5x
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 5/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-180K, showing cash burn in the current stored period.
- The balance sheet shows $43.3M of cash versus $3.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: GYRE decreased 0.1 points because Management declined by 2.2 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GYRE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.